**CURRICULUM VITAE**

**DATE:** 1 November 2020

**NAME:** Soko Setoguchi, M.D., Sc.M., Dr.P.H.

**PRESENT TITLE:** Professor of Medicine and Epidemiology, Rutgers Robert Wood Medical School and Rutgers School of Public Health, respectively

**HOME ADDRESS:** 50 Littlebrook Road, Princeton, NJ, 08540

**OFFICE ADDRESS:** Rutgers Institute for Health, 112 Paterson St, Rm 402, New Brunswick, NJ 08901

**TELEPHONE NUMBER:** 848-932-6507 (Office); 919-699-5926 (Mobile)

**E-MAIL ADDRESS:** soko.setoguchi@rutgers.edu

**CITIZENSHIP:** Japan

**EDUCATION:**

A. Undergraduate

 *N/A*

B. Graduate and Professional

*Miyazaki Medical College*

*Miyazaki, Japan*

*Degree: M.D. Date Awarded: 1994*

*Harvard School of Public Health, Health Care Management*

*Cambridge, MA*

*Degree: M.P.H. Date Awarded: 2002*

*Harvard School of Public Health, Dept. of Health Policy and Management*

*Cambridge, MA*

*Degree: Sc.M. Date Awarded: 2003*

*Harvard School of Public Health, Dept. of Epidemiology*

*Cambridge, MA*

*Degree: Dr.P.H. Date Awarded: 2005*

**POSTGRADUATE TRAINING:**

A. Internship and Residencies

*Kameda Medical Center, Kamogawa City, Japan*

*Resident*

*1994-1996*

*Kuakini Hospital, Univ of Hawaii-Honolulu*

*Sub-intern*

*1996*

*University of Iowa Hospitals & Clinics*

*Intern, Internal Medicine*

*1997-1998*

*Harvard University Health Service*

*Intern - Quality Improvement Project*

*2002-2003*

*University of North Carolina Hospitals*

*Resident, Internal Medicine*

*2014-2016*

*Rutgers**Robert Wood Johnson Medical School*

*Resident, Internal Medicine*

*2016-2017*

B. Research Fellowships

*Kyushu University Hospital*

*Clinical & Research Fellow, Cardiology*

*1998-2001*

 *Brigham & Women’s Hospital*

 *Visiting Research Fellow, Div of Pharmacoepidemiology*

 *2003-2004*

 *Brigham & Women’s Hospital & Harvard Medical School*

 *Research Fellow, Div. of Pharmacoepidemiology & Pharmacogenomics*

 *2004-2005*

 *Biomedical Informatics, sponsored by National Library of Medicine*

*MBL/NLM Fellow, Marine Biological, Woods Hole, MA*

*May 2012*

 C. Postdoctoral Appointments

*N/A*

**MILITARY:** *N/A*

**ACADEMIC APPOINTMENTS:**

*Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,*

*Brigham and Women’s Hospital, Harvard Medical School*

*Instructor of Medicine*

 *2005-2009*

*Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,*

*Brigham and Women’s Hospital, Harvard Medical School*

*Assistant Professor of Medicine*

*2009-2010*

*Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,*

*Brigham & Women’s Hospital*

*Director of Safety and Outcomes Research in Cardiology*

*2009–2010*

*Department of Epidemiology*

*Harvard School of Public Health*

*Assistant Professor of Epidemiology (Secondary Appointment)*

 *2009-2012*

*Department of Medicine*

*Duke Clinical Research Institute and Duke University School of Medicine*

*Associate Professor of Medicine*

 *2010-2014*

*Department of Pharmacoepidemiology*

*University of Tokyo, Graduate School of Medicine, Japan*

*Adjunct Associate Professor of Pharmacoepidemiology*

 *2011-2014*

*Department of Medicine*

*Duke Clinical Research Institute and Duke University School of Medicine*

*Adjunct Associate Professor of Medicine*

 *2014-2017*

*Department of Epidemiology*

*Rutgers School of Public Health/Institute for Health, Health Care Policy and Aging Research, Rutgers University*

*Adjunct Associate Professor of Epidemiology*

 *2016-2017*

*Division of Education, Department of Medicine*

*Rutgers Robert Wood Johnson Medical School/Institute for Health, Health Care Policy and Aging Rutgers, the State University of New Jersey*

*Associate Professor of Medicine*

 *2017-*

*Division of Education, Department of Medicine*

*Rutgers Robert Wood Johnson Medical School/Institute for Health, Health Care Policy and Aging Rutgers, the State University of New Jersey*

*Director of Clinical Research Education*

 *2017-*

*Department of Epidemiology*

*Rutgers School of Public Health/Institute for Health, Health Care Policy and Aging Research, Rutgers, the State University of New Jersey*

*Associate Professor of Epidemiology*

*2017-*

*Rutgers School of Graduate Studies*

*Rutgers, the State University of New Jersey*

*Co-Director of Master of Science in Clinical and Translational Science (MSCTS)*

 *2019-*

*Internal Medicine Residency Program, Department of Medicine*

 *Rutgers Robert Wood Johnson Medical School*

 *Director of Clinician Researcher Track*

 *2019-*

*Division of Education, Department of Medicine*

*Rutgers Robert Wood Johnson Medical School/Institute for Health, Health Care Policy and Aging Rutgers, the State University of New Jersey*

*Professor of Medicine*

 *2020-*

**HOSPITAL APPOINTMENTS:**

*Gen. Medicine & Clinical Epidemiology*

*Kyoto University Graduate Sch of Medicine*

*Staff Physician*

*2001*

*General Medicine*

*Robert Wood Johnson University Hospital*

*Attending Physician*

*2017-*

**OTHER EMPLOYMENT OR MAJOR VISITING APPOINTMENTS:**

 *N/A*

**PRIVATE PRACTICE:** *N/A*

**LICENSURE:** *Medical Licensure – Japan/No. 368237/received 1994*

 *Medical Licensure – limited – Iowa/1997-1998*

 *Medical Licensure – limited - North Carolina/#208081/exp. 4/2017*

 *Medical Licensure – Full – New Jersey/received 2017*

**DRUG LICENSURE:**

*N/A*

**CERTIFICATION:**

*ECFMG Certificate/ ECFMG No. 05402649/1996 (valid indefinite)*

*American Board of Internal Medicine (ABIM) Certificate 2018/ABIM ID 247660 (valid 10 years)*

**MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:**

*Japanese Society of General Medicine*

*Member*

*1995-2002*

*Japanese Circulation Society*

*Member*

*1997-2002*

*International Society of Pharmacoepidemiology*

*Member*

*2003-2010*

*Organizing Committee for the 2nd Asian Conference for Pharmacoepidemiology Director of Educational Program Development*

*2006-2007*

*Heart Failure Society of America*

*Member*

*2006-2014*

*American Heart Association*

*Member*

*2006-2015*

*Global Development Committee, International Society of Pharmacoepidemiology Member*

*2007-Present*

*International Society of Pharmacoepidemiology*

*Fellow*

*2011-Present*

*Organizing Committee for the 4th Asian Conference for Pharmacoepidemiology Member*

*2008-2009*

*Organizing Committee for the 5th Asian Conference for Pharmacoepidemiology Member*

*2009-2010*

*Organizing Committee for the 6th Asian Conference for Pharmacoepidemiology Member*

*2010-2011*

*Core Scientific Committee for 2011 International Conference on Pharmacoepidemiology and Therapeutic Risk Management*

*Member*

*2010-2011*

*Advisory Committee for FDA Medical Device Epidemiology Network*

*Member*

*2011*

*Core Scientific Committee for 2012 International Conference on Pharmacoepidemiology and Therapeutic Risk Management*

*Member*

*2011-2012*

*Organizing Committee for the 7th Asian Conference for Pharmacoepidemiology Member*

*2011-2012*

*Organizing Committee for the 7th Asian Conference for Pharmacoepidemiology Co-Director of Educational Program Development*

*2011-2012*

*Core Scientific Committee for 2013 International Conference on Pharmacoepidemiology and Therapeutic Risk Management - Quebec, Canada*

*Member*

*2012-2013*

*Organizing Committee for the 8th Asian Conference for Pharmacoepidemiology Member*

*2012-2013*

*Core Scientific Committee for 2014 International Conference on Pharmacoepidemiology and Therapeutic Risk Management - Taipei, Taiwan*

*Chair*

*2012-2014*

*2013 Fellowship and Award Committee, International Society of Pharmacoepidemiology*

*Member*

*2013*

*2014 Fellowship and Award Committee, International Society of Pharmacoepidemiology*

*Member*

*2014*

*Organizing Committee for the 9th Asian Conference for Pharmacoepidemiology*

*Member*

*2014-2015*

*Core Scientific Committee for 2015 International Conference on Pharmacoepidemiology and Therapeutic Risk Management - Boston, MA*

*Member*

*2014-2015*

*Core Scientific Committee for 2017 International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada*

*Member*

*2016-2017*

*Steering Committee for Asian Conference for Pharmacoepidemiology*

*Member*

*2016-2017*

*Educational Sessions for Asian Conference for Pharmacoepidemiology - Brisbane, Australia*

*Director*

*2016-2017*

*Core Scientific Committee for 2017 International Conference on Pharmacoepidemiology and Therapeutic Risk Management – Prague, Czech Republic*

*Member*

*2017-2018*

*Steering Committee for Asian Conference for Pharmacoepidemiology*

*Member*

*2017-2018*

*Educational Sessions for Asian Conference for Pharmacoepidemiology – Xian, China*

*Director*

*2017-2018*

*KDIGO Controversies Conference on Heart Failure in CKD*

*Invited Member*

*2017*

*Core Scientific Committee for 2018 International Conference on Pharmacoepidemiology and Therapeutic Risk Management – Philadelphia, USA*

*Member*

*2018-2019*

*Steering Committee for Asian Conference for Pharmacoepidemiology*

*Member*

*2018-2019*

*Educational Sessions for Asian Conference for Pharmacoepidemiology – Kyoto, Japan*

*Director*

*2018-2019*

**HONORS AND AWARDS:**

*Training Scholarship*

*Japan Scholarship Foundation*

*1989*

*Exchange Fellowship in Epidemiology*

*St. Luke’s Life Science Institute, Japan*

*2000*

*Pharmacoepidemiology Training and Research Scholarship*

*Harvard School of Public Health, Dept. of Epidemiology*

*2003*

*1st place abstract, ‘The Risk of Statins on Breast, Colorectal and Lung Cancer’*

*International Conference for Pharmacoepidemiology in Lisbon, Portugal*

*2006*

*Fellow*

*International Society of Pharmacoepidemiology (FISPE)*

*2011*

**BOARDS OF DIRECTORS/TRUSTEES POSITIONS:** *N/A*

**SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:**

*Wellcome Trust, 2007*

*South Carolina Research Centers of Economic Excellence Program, 2008*

*PCORI RFA Phase I (Cycle II), Reviewer, 2012*

*The Swiss National Science Foundation, 2013*

*AHRQ R21 (HS14-07 Deliberative approaches), Reviewer, 2014*

*PCORI Methodology Consultation Review Panel for Pragmatic Trial Proposals, 2014*

 *PCORI CDRN Phase II, Reviewer, 2015*

*PCORI Methodology Consultation Panel for Funded Pragmatic Trial Proposals, 2015-2016*

*AHRQ Special Emphasis Panel/Scientific Review Group 2017/05 ZHS1 HSR-X (01), Reviewer, 2016*

*AHRQ R18, Special Emphasis Panel/Scientific Review Group 2018/01 ZHS1 HSR-X (01), Reviewer 2018*

*NIH NCATS Special Emphasis Panel/Scientific Review Group UG3/UH3
Reviewer 2018*

*NIH NIEHS Special Emphasis Panel/Scientific Review Group K99/R01*

*Reviewer 2020*

**SERVICE ON MAJOR COMITTEES:**

1. International (Name, Inclusive Dates)

N/A

B. National (Name, Inclusive Dates)

*National Research and Development Project Committee for Medical Educational Programs, “A Model Core Curriculum for Medical Education, Educational Content Guidelines” - funded by the Ministry of Education, Japan, 1999-2000*

*Technical Advisory Panel for AHRQ DEcIDE Contract for Database Linkage, 2013*

*IOM/PCORI Workshop on Data Harmonization for Patient-Centered Clinical Research, 2013*

*PCORI CTAP Post-Award Expert Advisory Subcommittee, Member, 2015*

*PCORI Methodology Consultation Panel for Funded Pragmatic Trial Proposals, Consultant 2015-2016*

*FDA Drug Safety and Risk Management Advisory Committee (DSaRM), Member, 2017-Present*

C. Medical School/University (Name, Inclusive Dates)

 *Master of Science in Clinical and Translational Sciences Core Curriculum Committee, Co-Chair, Rutgers School of Graduate Studies 2019-present*

 *Clinical Investigator Search Committee, Rutgers Biomedical and Health Sciences, Member 2019-present*

 *Professor of Epidemiology and Associate Dean for Research Faculty Search Committee, Rutgers School of Public Health, Member 2019-present*

D. Hospital (Name, Inclusive Dates)

*Faculty Search Committee, Division of Pharmacoepidemiology, Brigham and Women’s Hospital and Harvard Medical School, 2009*

E. Department (Name, Inclusive Dates)

*Admission Committee for Pharmacoepidemiology Candidates, Department of Epidemiology, Harvard School of Public Health, 2010*

F. Editorial Boards (Journal Name, Inclusive Dates)

 *Journal of Clinical Pharmacology & Pharmacoepidemiology, Editorial Board Member, 2007-2014*

 *Pharmacoepidemiology & Drug Safety, Editorial Board Member, 2018-present*

 *Circulation Reports/Circulation Journal, Statistical Consulting Editor, 2018-present*

G. AdHoc Reviewer (Journal Name, Inclusive Dates)

 *Annals of Epidemiology, 2005*

*Journal of Affective Disorders, 2006*

*Arthritis Care and Research, 2006- present*

*Clinical Chemistry and Laboratory Medicine, 2006*

*Journal of the American College of Cardiology, 2006- present*

*Journal of the American Medical Association, 2006- present*

*American Journal of Epidemiology, 2006- present*

*Journal of Clinical Epidemiology, 2006- 2013*

*Pharmacoepidemiology and Drug Safety, 2006- present*

*BMC Family Practice, 2006*

*European Journal of Pediatrics, 2007*

*Pharmacoeconomics, 2007*

*Seminars in Arthritis and Rheumatism, 2007*

*Epidemiology, 2007 - 2012*

*Japanese Journal of Pharmacoepidemiology, 2007*

*Cancer Detection and Prevention, 2007*

*JAMA Internal Medicine, 2007- present*

*American Journal of Kidney Diseases, 2007 - present*

*Clinical Gastroenterology and Hepatology, 2007 - present*

*Journal of Rheumatology, 2007 - present*

*Nature Clinical Practice Rheumatology, 2007*

*Arthritis and Rheumatism, 2007 - present*

*American Journal of Cardiology, 2007 - present*

*Medical Care, 2008 - present*

*Journal of Clinical Pharmacology & Pharmacoepidemiology, 2008*

*British Medical Journal, 2008 - present*

*Lancet, 2008 - present*

*Circulation: Heart Failure, 2008 – 2012*

*Journal of Women’s Health, 2008*

*American Journal of Critical Care, 2008*

*Annals of Internal Medicine, 2009*

*Journal of Infectious Disease, 2009*

*Circulation, 2009-present*

*BMC Bioinformatics, 2010*

*American Journal of Pharmacotherapy, 2010*

*Circulation: Cardiovascular Quality and Outcomes, 2012-present*

*Pediatric Pulmonology 2018*

**SERVICE ON GRADUATE SCHOOL COMMITTEES:**

*Admission Committee for Pharmacoepidemiology Candidates, Department of Epidemiology, Harvard School of Public Health, 2010*

**SERVICE ON HOSPITAL COMMITTEES:**

*Faculty Search Committee, Division of Pharmacoepidemiology, Brigham and Women’s Hospital and Harvard Medical School, 2009*

**SERVICE TO THE COMMUNITY:** *N/A*

**SPONSORSHIP (Primary Mentorship) OF CANDIDATES FOR POSTGRADUATE DEGREE:**

*Wei Liu Master of Science in Pharmacoepidemiology, Harvard School of Public Health, 2007-2008*

*Hiraku Kumamaru, Doctor of Science in Pharmacoepidemiology, Harvard School of Public Health 2008-2011*

*Qian Li, Master of Science candidate in Pharmacoepidemiology, Harvard School of Public Health, Doctoral candidate in Pharmacoepidemiology, Harvard School of Public Health, 2009- 2011 and 2012-2013*

*Sophie Zhu, Prospective PhD student, Department of Biostatistics, University of*

*Tokyo, Japan, 2011-2016*

**SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS:**

*Winson Cheung, Summer fellow in the Division of Pharmacoepidemiology, Brigham and Women's Hospital, Assistant Professor, University of British Columbia, 2009-2014*

*Jessica Jalbert, Postdoctoral fellow in the Division of Pharmacoepidemiology, Brigham and Women's Hospital (2010-2012), Senior Epidemiologist, LA-SER Analytica, New York, NY (2012-present), 2010-2013*

*Natasha Chen, Postdoctoral fellow in the Division of Pharmacoepidemiology, Brigham and Women's Hospital, Epidemiologist, Food and Drug Administration, Silver Spring, BA (2013-present), 2010-2013*

*Edward Lai, Postdoctoral Fellow, Duke Clinical Research Institute, 2013-2015, Assistant Professor, National Cheng Kung University, Taiwan*

**TEACHING RESPONSIBILITIES:**

A. Lectures or Course Directorships

*Kyushu University School of Medicine, Introduction to Clinical Skills, Tutor, 4 hours preparation /week, 3 contact hours/week, 1998-1999*

*Kyushu University School of Medicine, Clinical Epidemiology Journal Club, Tutor, 2 hours preparation /week, 1 contact hours /week, 1998-2000*

*Kyushu University School of Medicine, Introduction to Physical Examination, Tutor and Course Director, 2 hours preparation /week, 1 contact hour /week, 1998-2000*

*Kyushu University School of Medicine, ACLS Training Course, Lecturer, Tutor and Course Director, 6 hours preparation /week for 3 months, 2 contact days, 1999-2000*

*Kyoto University, School of Medicine****,*** *ACLS Instructor Course, Lecturer, Tutor and Course Director, 6 hours preparation/week for one month, 2 contact days, 2000*

*Kyoto University, School of Medicine,**ACLS Training Course, Lecturer, Tutor and Course Director, 6 hours preparation/week for two months, 3 contact days, 2000*

*Harvard School of Public Health, Analytical Aspects of Clinical Epidemiology, Teaching Assistant, 30 min preparation, 2 contact hours/week for 4 weeks, 2004*

*Harvard School of Public Health, Advanced Pharmacoepidemiology, Guest Lecturer, 2 hours preparation time, one contact hour, 2004*

*Harvard Medical School, Pharmacoepidemiology and Pharmacoeconomics Module - Principles of Pharmacology for the Clinical Investigator, Group Discussion Facilitator, 1 hour preparation, 3 contact hours, 2007-2009*

*Harvard School of Public Health, Case-based Seminar in Pharmacoepidemiology, Co-director, 4 hour preparation for per week for 8 weeks, two 2 hour sessions per week for 8 weeks, 2008-2014*

*Harvard School of Public Health, Epidemiology Methods in Health Services Research, Director, 10 hour preparation for per week for 8 weeks, two 2 hour sessions per week for 8 weeks, 2010*

*Fuqua Business School, Secondary Use of Healthcare Data, Director, 10 hour preparation for per week for 8 weeks, two 2 hour sessions per week for 6 weeks, 2011-2014*

*University of Tokyo, Principles and Practice of Pharmacoepidemiology Using Large Databases, Director, 10 hour preparation for per week for 4 weeks, four 1.5 hour sessions per day for 2 days, 2011-2014*

 *Rutgers School of Graduate Studies, Rutgers, the State University of New Jersey,*

 *Co-Director of Master of Science in Clinical and Translational Science (MSCTS), 2019-*

*Internal Medicine Residency Program, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Director of Clinician Researcher Track*, *2019-*

B. Research Training

Post-Doctoral Fellows, Staff, and Faculty:

*Mitsuyo Kinjo, Rheumatologist and Educator, Okinawa Chubu Hospital, Okinawa, Japan, 2005-2014*

*Mahoto Kato, Research fellow in Cardiovascular Division, Brigham and Women' s Hospital, 2008-2010,*

*Assistant Professor, Department of Cardiology, Tokyo Medical School, Japan*

*Garrick Stewart, Clinical fellow in Cardiovascular Division, Brigham and Women' s Hospital, 2010- 2011*

*Instructor, Cardiovascular Division, Brigham and Women’s Hospital*

*Hiraku Kumamaru, Doctoral Candidate in Pharmacoepidemiology, Harvard School of Public Health, 2010-2014*

*Assistant Professor, University of Tokyo (2015-2019)*

*Xiojuan Mi, Staff biostatistician, Duke Clinical Research Institute, 2010-2014*

*Ching-Lan Chen, Postdoctoral fellow, Institute of Clinical Pharmacy, National Cheng Kung University, Taiwan, Assistant Professor, Institute of Clinical Pharmacy, National Cheng Kung University, Taiwan, 2011-2012*

*Kathleen Unroe, Fellow in Geriatrics, Duke Medical Center, Assistant Professor of Medicine, Indiana University, 2010-2011*

*Emil Fosbol, Research fellow, Duke Clinical Research Institute, 2011-2012*

*Yinghong Zhang, Staff biostatistician, Duke Clinical Research Institute, 2013- 2014*

*Izumi Sato, Visiting Research Scholar, Institute for Health, Rutgers Biomedical Health Sciences, Assistant Professor, Department of Pharamcoepidemiology, Kyoto University, Kyoto, Japan (2013-present), 2016-2020*

*Benjamin Bates, Resident, Internal Medicine, Robert Wood Johnson Medical School, Fellow with the Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, Master’s Candidate in Clinical and Translational Science, Rutgers Robert Wood Johnson Graduate School, 2018-2020*

*Thomas Nahass, Resident, Internal Medicine, Robert Wood Johnson Medical School, Fellow with the Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, 2018-2020*

*Poonam Gandhi, Staff data analyst, Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy, and Aging Research, 2019-present*

*Richard Hajjar, Chief Resident, Internal Medicine, Rutgers New Jersey Medical School, 2019-2020*

*Chintan Dave, Assistant Professor, Rutgers School of Pharmacy/Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy, and Aging Research, 2019-present*

*Ehimare Akhabue, Assistant Professor, Rutgers Robert Wood Johnson Medical School/ Rutgers Institute for Health, Health Care Policy, and Aging Research, 2019-present*

*Benjamin Bates, Postdoctoral fellow in cancer and cardiooncology pharmacoepidemiology, the Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, Master’s Candidate in Clinical and Translational Science, Rutgers Robert Wood Johnson Graduate School, 2020-present*

Pre Doctoral Students:

*Lauren Williams, Research assistant in the Division of Pharmacoepidemiology, Brigham and Women's Hospital, 2010-2013*

*Andrew Rothman, Research assistant in the Division of Pharmacoepidemiology, Brigham and Women's Hospital, Doctoral candidate in Pharmacoepidemiology, Harvard School of Public Health, 2010-2012*

*Lin Li, Doctoral candidate in Epidemiology, Boston University School of Public Health, Assistant Professor in Epidemiology, Boston University School of Public Health, 2010-2012*

*Joshua Gilman, Medical Student, Rutgers Robert Wood Johnson Medical School, 2018-2019*

*Marlena Sabatino, Medical Student, Rutgers Robert Wood Johnson Medical School, 2019-present*

*Kelly Gao, Medical Student, Chancellor’s Scholor, Rutgers Robert Wood Johnson Medical School, 2019-2020*

*Keita Tsuyuguchi, Visiting Research Scholar, Institute for Health, Rutgers Biomedical Health sciences, PharmD Student, Division of Pharmacy and Pharmaceutical Science, Kanazawa University*

*2019-2020*

*Add Hilary*

*Add Nate*

*Add Elaine*

**CLINICAL RESPONSIBILITIES:**

*Attending Physician, General Medicine Inpatient Teaching Service, Robert Wood Johnson Hospital, 2018- present*

**GRANT SUPPORT:**

A. Principal Investigator

*1. NIH/NICHD, R21-HD055479-01: Utility of a New Database to Study Drug Safety during Pregnancy, 2007-2010, $470,000*

*2. AHRQ, HHSA290-2005-0016-I: Comparative Effectiveness of Angiotensin Blockers for Hypertension in Elderly Patients with Cardiovascular Comorbidities, 2008-2010, $450,000*

*3. AHRQ, KO2-HS017731 (mid-career development award): Improving Methods for Comparative Effectiveness Research in Cardiovascular Care, 2008-2013, $800,000*

*4. AHRQ, HHSA290-2005-0016-I: Real World Effectiveness of Implantable Cardioverter Defibrillators and Carotid Stenting in Medicare Patients, 2009-2011, $1,900,000*

*5. Amerigroup Inc., Develop a prediction model for nursing home admission using novel data including detailed information on functional status, cognitive function, and care providers in community dwelling elderly, 2012-2013, $125,000*

*6. Johnson and Johnson: Surveillance of Health Care in Asian Network (SCAN) Project:*

*Infrastructure Development and Analysis with the Asian Pharmacoepidemiology Network (AsPEN), 2013-2015, $1,400,000*

*7. NIH/NIA, R21 Climate Change and Health: Heat Wave and Drug Adverse Events in the Elderly, 2013-2015, $430,000*

*8. PCORI, Method RFA: Developing Methods for Linking Large Databases and Registries, 2014-2016, $1,400,000*

*9. Pfizer Inc., Validity of diagnoses for RA, cancer and infectious diseases in Japan, 2017-2019, $500,000*

*10.* *Pfizer Japan, Validity of Claims Based Definition for Ulcerative Colitis in Japan 2018-2020, $190,693*

*12. Pfizer Inc., Investigator-Initiated Research (IIR), Modifying the Risk and Outcome of Heart Failure in Patients with Rheumatoid Arthritis. Is tofacitinib a better option compared to other DMARDs?, 2018-2020, $782,557*

*13. NIH/NIA, R01-PA-17-088: Disease Outcomes in Older adults under extreme Heat, Air pollution and Medication use (DO-NO-HARM), 2019-2024, $3,062,016*

*14. Asian Research Center for Minority Aging Research (RCMAR), Health Outcomes in Asian Older Adults under Extreme Heat and Medication Use. 2019-2020, $35,000*

*15. Bristol Meyer Squibb, Characterizing the Acute Heart Failure Patient Population in Japan, 2019-2020****,*** *$83,987*

*15. Cystic Fibrosis Foundation:* *Building Data Infrastructure for Clinical Research in Patients with Cystic Fibrosis, 2020-2021, $122,000, PI Setoguchi*

*Add*

*Pfizer PE DVT feasibility fund*

*Pfizer NDB feasibility fund*

*Pfizer PE DVT study*

*Pizer ILD study*

*CTSA supple*

*?Daiichi cancer*

*? Merck MIDNET*

B. Co-Investigator/Mentor

*1. NIH/AHRQ, 2 R01 HS10881: Consequences of Drug Cost Sharing: A New Randomized Trial, 2000-2008, $2,320,000*

*2. NIH/NIA, 1 R01 AG21950: Effects of Income-based Drug Charges in Older Patients, 2003-2008, $1,312,000*

*3. NIA, R01 AG023178: Propensity Scores and Preventive Drug Use in the Elderly, 2005-2007, $300,000*

*4. NIH, U01 MH078708-01: Antidepressant Use and Suicidality: Comparative Safety in Children and Adults, 2006-2010, $1,238,000*

*5. AHRQ, HHSA29020050016I: Testing Cancer Quality Measures for End of life Care, 2006-2007, $400,000*

*6. American Heart Association, AHA-PRT Outcomes Research Center Grant, $817,810*

*7. Johnson & Johnson, Link Medicare claims with registry data to analyze detailed impatient clinical data in conjunction with post-discharge outcomes data on a real world cohort of patients recently hospitalized with heart failure and examine the impact of quality care initiative on HF outcomes. Phase III is an add-on analyses that incorporates Long-Term Outcomes in ADHERE Registry*

*8. Arthritis Foundation, Treatment Plans for Polyarticular JIA, 2013-2014*

*9. NIAMS, 1R01-AR063890-01: Enhancing the CARRA: Integration and Dissemination of Clinical, 2013-2014, $1,000,000*

*10. NIH/NCATS, UL1TR003017, New Jersey Alliance for Clinical and Translational Science: NJ ACTS, 2019-2024, $3,214,394*

*11. NIH/NCATS, KL2 Career Development Award, New Jersey Alliance for Clinical and Translational Science: NJ ACTS, 2019-2020, $126,500, Primary Mentor to Chintan Dave, Pharm D, PhD*

*Add*

*NJCCR*

*Patterson Trust Mentored Research Award*

*?Diversity for Ehi*

C. Pending

*1.NHLBI, R38 RFA-HL-18-023 Rutgers Stimulating Access to Research in Residency (R-StARR), 2020-2024, $1,352,696, Lead Co-PD Setoguchi*

*2. NIH, R01-PA-18-484: Prosthetic Joint Infection Prevention through Appropriate Use of Antibiotic Prophylaxis for Dental, GI and GU Procedures (PJI PROTECT), 2020-2025, $3,774,173, PI Setoguchi*

**PUBLICATIONS:**

A. Refereed Original Article in Journal

*1. Hirooka Y,* ***Setoguchi S****, Ando S, Egashira K, Takeshita A; A role of Tetrahydrobiopterin on abnormal peripheral circulation in patients with congestive heart failure; Rinshoyakuri no shinpo, 22: 24-129, 2001.*

1. *Hidaka I, Ando S, Shigematsu H, Sakai K,* ***Setoguchi S****, Seto T, Hirooka Y, Takeshita A. Yamamoto Y; Noise-enhanced heart rate and sympathetic nerve responses to oscillatory lower body negative pressure in humans; Journal of Neurophysiology, 86(2): 559-64, 2001.*
2. ***Setoguchi S****, Mohri M, Shimokawa H, Takeshita A; Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease; Journal of the American College of Cardiology, 38(2): 493-8, 2001.*
3. *Tsuchihashi M, Tsutsui H, Kodama K, Kasagi F,* ***Setoguchi S****, Mohr M, Kubota T, Takeshita A; Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure; American Heart Journal, 142(4): 20A-26A, 2001.*
4. *Masumoto A, Hirooka Y, Hironaga K, Eshima K,* ***Setoguchi S****, Egashira K, Takeshita A; Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin); American Journal of Cardiology, 88(11): 1291-4, 2001.*
5. *Masumoto A, Hirooka Y, Shimokawa H, Hironaga K,* ***Setoguchi S****, Takeshita A; Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans; Hypertension, 38(6): 1307-10, 2001.*
6. ***Setoguchi S****, Hirooka Y, Eshima K, Shimokawa H, Takeshita A; Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure; Journal of Cardiovascular Pharmacology, 39(3): 363-8, 2002.*
7. *Hirooka Y, Eshima K,* ***Setoguchi S****, Kishi T, Egashira K, Takeshita A; Vitamin C improves attenuated angiotensin II-induced endothelium-dependent vasodilation in human forearm vessels; Hypertension Research, 26(12): 953-959, 2003.*
8. *Kinjo M,* ***Setoguchi S****, Schneeweiss S, Solomon DH; The association between bone mineral density and neurologically active medications: Results from NHANES III; Am J Med, 118(12):1414, 2005.*
9. ***Setoguchi S****, Solomon DH, Avorn J, Weinblatt ME, Katz JN, Glynn RJ, Cook EF, Schneeweiss S; Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis; Arthritis Rheum, 54(9): 2757-64, 2006.*
10. *Solomon DH, Avorn J, Katz JN, Weinblatt ME,* ***Setoguchi S****, Levin R, Schneeweiss S; Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis; Arthritis Rheum, 54(12): 3790-8, 2006.*
11. *Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J,* ***Setoguchi S****, Canning C, Schneeweiss S; Patterns of cardiovascular risk in rheumatoid arthritis; Ann Rheum Dis, 65(12):1608-12, 2006.*
12. *Wang PS, Brookhart MA,* ***Setoguchi S****, Patrick AR, Schneeweiss S; Psychotropic medication use for behavioral symptoms of dementia; Curr Neurol Neurosci Rep, 6(6): 490-5, 2006.*
13. ***Setoguchi S****, Glynn RJ, Avorn J, Mogun H, Schneeweiss S; Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly; Circulation, 115(1): 27-33, 2007.*
14. *Schneeweiss S,* ***Setoguchi S****, Brookhart MA, Canning CF, Wang PS; Comparative Safety of Conventional and Atypical Antipsychotic Medications: Risk of Death in British Columbia Seniors; CMAJ, 176(5): 627-32, 2007.*
15. *Charytan DM,* ***Setoguchi S****, Solomon DH, Avorn J, Winkelmayer WC; Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease; Kidney Int., 71(9): 938-945, 2007.*
16. ***Setoguchi S****, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S; Agreement of Diagnosis and its Date for Hematologic Malignancies and Solid Tumors between Medicare Claims and Cancer Registry Data; Cancer Causes Control, 18(5): 561-9, 2007.*
17. ***Setoguchi S****, Stevenson LW, Schneeweiss S; Repeated Hospitalizations Predict Mortality in the Community Population with Heart Failure; Am Heart J, 154(2): 260-6, 2007.*
18. *Schneeweiss S,* ***Setoguchi S****, Weinblatt M, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH; Anti-TNFα therapy and the risk of serious bacterial infections; Arthritis Rheum, 56(6): 1754-64, 2007.*
19. ***Setoguchi S****, Glynn RJ, Avorn J, Levin R, Winkelmayer WC; Ten-Year Trends of Cardiovascular Drug Use after Myocardial Infarction among Community Dwelling Persons ≥65 Years of Age; American Journal of Cardiology, 100(7):1061-1067, 2007.*
20. *Wang PS, Schneeweiss S,* ***Setoguchi S****, Patrick A, Avorn J, Mogun H, Choudhry NK, Brookhart MA; Ventricular Arrhythmias and Cerebrovascular Events in the Elderly Using Conventional and Atypical Antipsychotic Medications; J Clin Psychopharmacol, 27(6): 707-710, 2007.*
21. ***Setoguchi S****, Levin R, Winkelmayer WC; Long-Term Trends of Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use after Heart Failure Hospitalization in Community-Dwelling Seniors; International Journal of Cardiology, 125(2): 172-7, 2008.*
22. *Kinjo M,* ***Setoguchi S****, Solomon DH; Bone Mineral Density in Older Adult Patients with Rheumatoid Arthritis: An Analysis of NHANES III; Journal of Rheumatology, 34(10): 1971-5, 2007.*
23. *Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME;* ***Setoguchi S****; Avorn J; Levin R; Solomon DH; Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal; Arthritis Rheum (Arthritis Care Research), 57: 928-934, 2007.*
24. *Kinjo M,* ***Setoguchi S****, Solomon DH; Bone Mineral Density in Adults with the Metabolic Syndrome: Analysis in a Population-based United States Sample; J Clin Endocrinol Metab, 92(11): 4161-4, 2007.*
25. *Nagata T,* ***Setoguchi S****, Hemenway D, Perry M; The effectiveness of a law to reduce alcohol-impaired driving in Japan; Injury Prevention, 14 (1): 19-23, 2007.*
26. ***Setoguchi S****, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC; Improvements in Long-term Mortality after Myocardial Infarction and Increased Use of Cardiovascular Drugs after Discharge: A 10-Year Trend Analysis; Journal of American College of Cardiology, 51(13): 1247-54, 2008.*
27. ***Setoguchi S****, S Schneeweiss, Brookhart MA, Glynn RJ, Cook EF; Evaluating Uses of Data Mining Techniques in Propensity Score Estimation: A Simulation Study; Pharmacoepidemiology and Drug Safety, 17(6): 546-55, 2008.*
28. ***Setoguchi S,*** *Solomon DH, Levin R, Winkelmayer WC; Gender Differences in the Management and Prognosis of Myocardial Infarction among Patients >= 65 Years of Age; American Journal of Cardiology, 101(11): 1531-6, 2008.*
29. ***Setoguchi S****, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH; Tumor necrosis factor - α antagonist use and heart failure in elderly patients with rheumatoid arthritis; Am Heart J., 156(2): 336-4, 2008.*
30. *Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S,* ***Setoguchi S****, Mogun H, Avorn J, Sturmer T; Subgroup analyses to determine cardiovascular risk associated with NSAIDs and coxibs in specific patient groups; Arthritis Rheum (Arthritis Care Research), 9(8):1097-1104, 2008.*
31. ***Setoguchi S****, Wang PS, Brookhart MA, Canning C, Schneeweiss S; Potential Causes of Higher Mortality Among Elderly Users of Conventional vs. Atypical Antipsychotics; J Am Geriatr Soc., 56(9): 1644-50, 2008.*
32. ***Setoguchi S****, Earle CC, Glynn RJ, Stedman M, Polinski JM, Corcoran CP Haas JS; Comparison of Prospective and Retrospective Indicators of the Quality of End-of-Life Cancer Care; Journal of Clinical Oncology, 26(35): 5671-8, 2008.*
33. *Winkelmayer WC, Levin R,* ***Setoguchi S****; Associations of kidney function with cardiovascular medication use after myocardial infarction; Clin J Am Soc Nephrol, 3: 1415-1422, 2008.*
34. *Winkelmayer WC,* ***Setoguchi S,*** *Levin R, Solomon DH; Comparing cardiovascular outcomes in older patients with diabetes who initiated rosiglitazone versus pioglitazone therapy; Arch Int Med., 168(21): 2368-75, 2008.*
35. *Kinjo M,* ***Setoguchi S****, Solomon DH; Anti-histamine Therapy and Bone Mineral Density: Analysis in a Population-Based U.S. Sample; Am J Med., 121(12): 1085-91, 2008.*
36. *Choudhry NH,* ***Setoguchi S****, Levin R, Winkelmayer WC, Shrank WH; Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients; Pharmacoepidemiology and Drug Safety, 17(12): 1189-96, 2008.*
37. ***Setoguchi S****, Nohria A, Rassen J, Stevenson LW, Schneeweiss S; Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure; CMAJ, 180: 611-6, 2009.*
38. *Schneeweiss S,* ***Setoguchi S****, Brookhart MA, Kaci L, Wang PS; Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data; CNS Drugs, 23: 171-80, 2009.*
39. ***Setoguchi S,*** *Higgins JM, Mogun H, Mootha VK, Avorn J; Propranolol and the Risk of Hospitalized Myopathy: Translating Chemical Genomics Findings into Population-level Hypotheses; Am Heart J, 159(3): 428-33, 2010.*
40. ***Setoguchi S****, Glynn RJ, Steadman M, Flavell CM, Levin R, Stevenson LW; 'Hospice, Opiates, and Acute Care Utilization Among the Elderly Prior to Death From Heart Failure or Cancer'; Am Heart J., 160(1): 139-44, 2010.*
41. *Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME,* ***Setoguchi S****, Greenberg JD; Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity; Ann Rheum Dis, 69(11):1920-5, 2010.*
42. ***Setoguchi S****, Choudhry N, Levin R, Shrank WH, Winkelmayer WC; Temporal Trends in Adherence to Cardiovascular Medications After Heart Failure Hospitalization in the Elderly; Clinical Pharmacology and Therapeutics, 88(4): 548-54, 2010.*
43. *Winkelmayer WC, Patrick AR, Liu J, Brookhart MA,* ***Setoguchi S****; The increasing prevalence of atrial fibrillation among hemodialysis patients; J Am Soc Nephrol, 22: 357–365, 2011.*
44. *Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed GW, Tsao P, Farkouh ME, Nasir A,* ***Setoguchi S****, Solomon DH;  TNF antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis; Ann Rheum Dis, 70(4): 576-82, 2011.*
45. ***Setoguchi S****, Shrank WH, Liu J, Lee JC, Saya U, Winkelmayer WC, Dreyer NA; Challenges in Comparing Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension in Medicare Data; Clin Pharmacol Ther, 89(5):674-82, 2011.*
46. *Li Q, Glynn RJ, Dreyer NA, Liu J, Mogun H,* ***Setoguchi S****; Validity of Claims-based Definitions of Impaired Left Ventricular Systolic Function in Medicare Patients; Pharmacoepidemiol Drug Saf, 20(7): 700-8, 2011.*
47. *Charytan DM, Patrick AR, Liu J,* ***Setoguchi S****, Herzog CA, Brookhart MA, Winkelmayer WC; Trends in the use and outcomes of implantable cardioverter defibrillators in patients undergoing dialysis in the United States; Am J Kidney Dis, 58(3): 409-17, 2011.*
48. *Winkelmayer WC, Liu J,* ***Setoguchi S****, Choudhry NK; Effectiveness and Safety of Warfarin Initiation in Older Hemodialysis Patients with Incident Atrial Fibrillation; Clin J Am Soc Nephrol, 6(11): 2662-8, 2011.*
49. *Winkelmayer WC, Liu J, Patrick AR,* ***Setoguchi S****, Choudhry NK; Prevalence of atrial fibrillation and warfarin treatment in older patients receiving hemodialysis; J Nephrol, 25: 341-35, 2011.*
50. *Rassen JA, Glynn RJ, Rothman KJ,* ***Setoguchi S****, Schneeweiss S; Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses; Pharmacoepidemiol Drug Saf; 21(7): 697-709, 2012.*
51. *Palmsten K,* ***Setoguchi S****, Dormuth C, Hernandez-Diaz; Elevated Risk of Preeclampsia in Pregnant Women with Depression:  Depression versus Antidepressants; Am J Epidemiol, 175(10): 988-97, 2012.*
52. *Hammill BG, Curtis LH,* ***Setoguchi S;*** *Performance of Propensity Score Methods When Comparison Groups Originate From Different Data Sources; Pharmacoepidemiol Drug Saf, 2: 81-9, 2012.*
53. *Liu W, Brookhart MA, Schneeweiss S, Mi X,* ***Setoguchi S****; Implication of Collider Stratification Bias in Epidemiologic Studies: A Simulation Study. Am J Epidemiol, 176(10): 938-48, 2012.*
54. *Unro KT, Greiner MA, Johnson KS, Curtis LH,* ***Setoguchi S****; Racial Differences in Hospice Use and Patterns of Care After Enrollment in Hospice Among Medicare Beneficiaries With Heart Failure; Am Heart J, 163(6): 987-993, 2012.*
55. *Cheung W, Stevenson LW, Stewart G,* ***Setoguchi S****; Enrollment and Events of Hospice Patients with Heart Failure versus Cancer; Journal of Pain and Symptom Management, 45(3): 552-560. 2013.*
56. *Margulis A,* ***Setoguchi S,*** *Mittleman MA, Glynn RJ, Dormuth RJ, Hernandez-Diaz S; Algorithms to Estimate the Beginning of Pregnancy in Administrative Databases; Pharmacoepidemiol Drug Saf., 22(1):16-24, 2013.*
57. *Kato M, Stevenson LW, Palardy M, Campbell PM, May CW, Lakddawala NK, Stewart G, Nohria A, Rogers JG, Heywood JT, Gheorghiade M, Lewis EF, Mi X,* ***Setoguchi S****; The Worst Symptom As Defined By Patients During Heart Failure Hospitalization: Implications for Response to Therapy; J Card Fail, 18(7): 524-33. 2012.*
58. *Curtis LH, Mi X, Qualls LG, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA,* ***Setoguchi S****, Hernandez AF, Fonarow GC; Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure; American Heart Journal, 163(6): 946-953, 2012.*
59. *Fosbol E, Peterson ED, Zhang Y, Iwata I, Curtis LH,* ***Setoguchi S****; Comparative Cardiovascular Safety of Dementia Medications: A Cross-National Study; J Am Geriatr Soc., 60(12): 2283-9, 2012.*
60. *Palmsten K, Hernandez-Diaz S, Kuriya B, Solomon DH,* ***Setoguchi S;*** *Use of Systemic Immunosuppressive Drugs and Risk of Preeclampsia During Pregnancy; AC&R, 64(11): 1730-8, 2012.*
61. *Li L,* ***Setoguchi S,*** *Cabral H, Jick S; Opioids and risk of type 2 diabetes in adults with non-cancer pain; Pain Physician, 16(1): 77-88, 2013.*
62. *Li L,* ***Setoguchi S****, Cabral H, Jick S; Opioid use for non-cancer pain and risk of myocardial infarction among adults; J Intern Med., 273(5): 511-26, 2013.*
63. *Sinner MF, Greiner MA, Mi X, Hernandez AF, Jensen PN, Piccini JP,* ***Setoguchi S****, Walkey AJ, Heckbert SR, Benjamin EJ, Curtis LH; Completion of guideline-recommended initial evaluation of atrial fibrillation; Clin Cardiol., 35(10): 585-93, 2013.*
64. *Goldstein BA, Arce CM, Hlatky MA, Turakhia M,* ***Setoguchi S,*** *Winkelmayer WC; Trends in the Incidence of Atrial Fibrillation in Older Patients Initiating Dialysis in the United States; Circulation, 126(19): 2293-30, 2012.*
65. *Hess PL, Greiner MA, Fonarow GC, Klaskala W, Mills RM, Setoguchi S, Al-Khatib SM, Hernandez AF, Curtis LH; Outcomes Associated With Warfarin Use in Older Patients With Heart Failure and Atrial Fibrillation and a Cardiovascular Implantable Electronic Device: Findings From the ADHERE Registry Linked to Medicare Claims; Clin Cardiol., 35(11): 649-57, 2012.*
66. *Al-Khatib SM, Mi X, Wilkoff BL, Qualls LG, Frazier-Mills C,* ***Setoguchi S****, Hess PL, Curtis LH; Follow-up of Patients with New Cardiovascular Implantable Electronic Devices: Are Experts' Recommendations Implemented in Routine Clinical Practice?; Circ Arrhythm Electrophysiol, 6(1): 108-16, 2013.*
67. *Li L,* ***Setoguchi S****, Cabral H, Jick S; Opioid use for non-cancer pain and risk of fracture in adults:  a nested case-control study using the General Practice Research Database; Am J Epidemiol. 178(4): 559-69, 2013.*
68. *Huybrechts KF, Palmsten K, Mogun H, Kowal M, Avorn J,* ***Setoguchi S****, Hernández-Díaz S; National trends in antidepressant medication treatment among publicly insured pregnant women; Gen Hosp Psychiatry, 35(3): 265-71, 2013.*
69. *Mi X, Hammill BG, Curtis LH, Greiner MA,* ***Setoguchi S****;**Impact of Immortal Person-Time and Time Scale in Comparative Effectiveness Research for Medical Devices: A Case for Implantable Cardioverter-Defibrillators; J Clin Epidemiol, 66(8 Suppl): S138-44, 2013.*
70. *Chen CY, Stevenson LW, Stewart GC, Seeger JD, Williams L, Jalbert JJ,* ***Setoguchi S****; Impact of Baseline Heart Failure Burden on Post-ICD Mortality among Medicare Beneficiaries; J Am Coll Cardiol, 61(21): 2142-50, 2013.*
71. *Cheung W, Levin R,* ***Setoguchi S****; Appropriateness of Cardiovascular Care in Elderly Cancer Survivors; Med Oncol, 30(2): 561, 2013.*
72. *Palmsten K, Huybrechts KF, Michels KB, Williams PL, Mogun H,* ***Setoguchi S****, Hernández-Díaz S; Antidepressant Use and Risk for Preeclampsia; Epidemiology, 24(5): 682-91, 2013.*
73. *Ooba N,* ***Setoguchi S****, Ando T, Sato T, Yamaguchi T, Mochizuki M, Kubota K; Claims-based Definition of Death in Japanese Claims Database: Validity and Implications; PLoS One, 8(5):e66116, 2013.*
74. *Palmsten K, Huybrechts KF, Mogun H, Kowal MK, Williams PL, Michels KB,* ***Setoguchi S****, Hernández-Díaz S; Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations; PLoS One, 8(6): e67405, 2013.*
75. *AsPEN collaborators, Andersen M, Bergman U, Choi NK, Gerhard T, Huang C, Jalbert J, Kimura M, Kimura T, Kubota K, Lai EC, Ooba N, Park BJ, Pratt N, Roughead EE, Sato T,* ***Setoguchi S****, Shin JY, Sundström A, Yang YH; The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia; Pharmacoepidemiol Drug Saf, 22(7): 700-4, 2013.*
76. *Bolognesi MP, Greiner MA, Attarian DE, Watters TS, Curtis LH, Berend KR, Wellman SS,* ***Setoguchi S****; Unicompartmental Knee Arthroplasty and Total Knee Arthroplasty Among Medicare Beneficiaries, 2000-2009; J Bone Joint Surg Am, 95(22): e174, 2013.*
77. *Bolognesi MP, Watters TS, Attarian DE, Watters TS, Berend KR, Wellman SS,* ***Setoguchi S****; Simultaneous vs. Staged Bilateral Total Knee Arthroplasty Among Medicare Beneficiaries, 2000-2009; The Journal of Arthroplasty, 28(8 Suppl): 87-91, 2013.*
78. *Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA,* ***Setoguchi S****, Hernandez AF, Fonarow GC; Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure; Am Heart J, 165(6): 979-986, 2013.*
79. *Vardi M, Yeh RW, Herzog CA, Winkelmayer WC,* ***Setoguchi S****, Charytan DM; Strategies for Post Marketing Surveillance of Drugs and Devices in Patients with End-Stage Renal Disease Undergoing Dialysis; Clin J Am Soc Nephrol, 8(12): 2213-20, 2013.*
80. *Palmsten K, Hernández-Díaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED****,*** *Mogun H,* ***Setoguchi S****; Antidepressant Use Near Delivery and Risk of Postpartum Hemorrhage in a Nationwide US Cohort of Low Income Women; BMJ, 347: f4877, 2013.*
81. *Eapen ZJ, Hammill BG,* ***Setoguchi S****, Schulman KA, Peterson ED, Hernandez AF, Curtis LH; Who Enrolls in the Medicare Part D Prescription Drug Benefit Program? Medication use among patients with heart failure; J Am Heart Assoc, 2(5): e000242, 2013.*
82. *G Lionetti, Y Kimura, LE Schanberg, T Beukelman, CA Wallace, NT Ilowite, J Winsor, K Fox, M Natter, JS Sundy, E Brodsky, JR Curtis, V Del Gaizo, S Iyasu, A Jahreis, A Meeker-O’Connell, BB Mittleman, BM Murphy, ED Peterson, SC Raymond,* ***S Setoguchi****, JN Siegel, RE Sobel, D Solomon, TR Southwood, R Vesely, PH White, NM Wulffraat, CI Sandborg; Using Registries to Identify Adverse Events in Rheumatic Diseases; Pediatrics, 132(5): e1384-94, 2013.*
83. *Raghunathan K, Shaw A, Nathanson B, Stürmer T, Brookhart A, Stefan MS,* ***Setoguchi S****, Beadles C, Lindenauer PK; Association between the choice of intravenous crystalloid and in-hospital mortality among critically ill adults with sepsis; Crit Care Med, 42(7): 1585-91, 2014.*
84. *Greiner MA, Qualls LG, Iwata I, White HK, Molony SL, Sullivan MT, Burke B, Schulman KA,* ***Setoguchi S****; Predicting Nursing Home Placement Among Home and Community-Based Services Program Participants; Am J Manag Care, 20(12): e535-6, 2014.*
85. *Huybrechts, KF, Palmsten K, Avorn J, Cohen, LS, Holmes LB, Franklin JM, Mogun, H, Levin R, Kowal M,* ***Setoguchi S****, Hernandez-Diaz S; Antidepressant Use in Pregnancy and the Risk of Cardiac Defects; N Eng J Med, 370(25): 2397-407, 2014.*
86. ***Setoguchi S****, Stevenson LW, Stewart GC, Bhatt DL, Epstein AE, Desai M, Wiilams L, Chen CY; Healthy candidate bias limits assessment of clinical effectiveness for implantable cardioverter-defibrillators: a cohort study of older patients with heart failure; BMJ, 348: g2866, 2014.*
87. ***Setoguchi S****, Zhu Y, Jalbert JJ, Williams L, Chen CY; Validity of Deterministic Record Linkage Using Multiple Indirect Personal Identifiers: Linking a Large Registry to Claims Data; Circ Cardiovasc Qual Outcomes, 7(3): 475-80, 2014.*
88. *Li X, Castillo WC, Stürmer T, Pate V, Gray CL, Simpson RJ,* ***Setoguchi S****, Hanson LC, Funk MJ****;*** *Utilization of Combination Antihypertensive Therapy Initiation in Older Americans Without Prevalent Cardiovascular Disease; J Am Geriatr Soc, 62(9): 1729-35, 2014.*
89. *Kumamaru H, Judd, SE, Curtis JR, Ramachandran R, MS; N. Hardy C, Rhodes JD, Safford MM, Kissela BM, Howard G, Jalbert JJ, Brott TG,* ***Setoguchi S****; Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: REGARDS Study Linked with Medicare Claims; Circ Cardiovasc Qual Outcomes, 7(4): 611-9, 2014.*
90. *Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, Kremer J, Solomon DH,* ***Setoguchi S****, Xie F, Yun H; Linkage of a De-identified United States Rheumatoid Arthritis Registry with Administrative Data to Facilitate Comparative Effectiveness Research; Arthritis Care Res, 66(12): 1790-8, 2014.*
91. *Halava H, Korhonen MJ, Huupponen R,* ***Setoguchi S****, Pentti J, Kivimäki M, Vahtera J; Lifestyle factors as predictors of nonadherence to statin therapy among individuals with and without cardiovascular comorbidities; CMAJ, 186(12): E449-56, 2014.*
92. *Li L,* ***Setoguchi S****, Jick S; Validity of non-fatal serious ventricular arrhythmia in UK-based Clinical Practice Research Datalink; Pharmacoepidemiology and Drug Safety, 23(9): 999-1001, 2014.*
93. *Jalbert JJ, Mi X, Chen CY, Curtis LH, Hammill BG,* ***Setoguchi S****; Methodological Considerations in Observational Comparative Effectiveness Research for Implantable Medical Devices: An Epidemiological Perspective; Am J Epidemiol, 180(9): 949-58, 2014.*
94. *Jalbert JJ, Nguyen LL, Gerhard-Herman ML, Jaff MR, White CJ, Rothman AT, Seeger JD, Kumamaru H, Williams LA, Chen CY, Liu J, Tsai TT, Aronow HD, Johnston JA, Brott TG,* ***Setoguchi S****; Outcomes After Carotid Artery Stenting in Medicare Beneficiaries 2005-2009; JAMA Neurol, 72(3): 276-86, 2015*
95. *Lai CC, Wong MB, Iwata I, Zhang Y, Hsieh CY, Kao Yang YH,* ***Setoguchi S****; Comparative Risk of Pneumonia Among New Users of Cholinesterase Inhibitors for Dementia; J Am Geriatr Soc, 63(5): 869-76, 2015.*
96. *Kumamaru H, Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Williams LA, Chen CY, Seeger JD, Liu J, Franklin JM,* ***Setoguchi S;*** *Surgeon Case Volume and 30-day Mortality after Carotid Endarterectomy among Contemporary Medicare Beneficiaries: Before and After National Coverage Decision for Carotid Artery Stenting; Stroke, 46(5): 1288-94, 2015.*
97. *Lai CC, Man KKC, Chaiyakunapruk N, Cheng CL,Chien HC,Chui CSL,Dilokthornsakul P,
Hardy NC, Hsieh CY, Hsu CY, Kubota K, Lin TC, Liu Y, Park BJ, Pratt N, Roughead EE, Shin JY, Watcharathanakij S, Wen J, Wong ICK, Kao Yang YH, Zhang Y,****SetoguchiS****; Brief Report: Databases in the Asia-Pacific Region: The Potential for a Distributed Network Approach; Epidemiology, 26(6): 815-20, 2015.*
98. *Zhu Y, Matsuyama Y, Ohashi Y,* ***Setoguchi S****; When to Conduct Probabilistic Linkage vs. Deterministic Linkage? A Simulation Study; J Biomed Inform, 56:80-6, 2015.*
99. *Chen CY, Stevenson LW, Stewart GC, Bhatt DL, Epstein AE, Desai M, Wiilams L,* ***Setoguchi S****; Real-World Effectiveness of Primary ICDs Implanted during Hospitalizations for Heart Failure Exacerbation or Other Acute Comorbidities: a Cohort Study of Older Patients with Heart Failure; BMJ, 351: h3529, 2015.*
100. *Zhu Y, Chen CY, Matsuyama Y, Oshashi Y, Franklin JM,* ***Setoguchi S****; Comparative Validity of Methods to Select Appropriate Cutoff Weight for Probabilistic Linkage Without Unique Personal Identifiers; Pharmacoepidemiol Drug Saf., 25(4): 444-52, 2016.*
101. *Cheung WY, Lai EC, Ruan JY, Chang JT,* ***Setoguchi S****; Comparative adherence to oral hormonal agents in older women with breast cancer; Breast Cancer Res Treat., 152(2): 419-27, 2015.*
102. *Lai CC, Kao-Yang Y, Yang YK, Lin SJ, Wong MB,* ***Setoguchi S****; Comparative Risk of Oral Ulcerations among Antipsychotics Users - population based retrospective cohort study; Pharmacoepidemiol Drug Saf., 25(2): 123-32, 2016.*
103. *Jalbert JJ, Gerhard-Herman MD, Nguyen LL, Jaff MR, Kumamaru H, Williams LA, Chen CY, Liu J, Seeger JD, Rothman AT, Schneider P, Brott TG, Tsai TT, Aronow HD, Johnston JA,* ***Setoguchi S****; Relationship Between Physician and Hospital Procedure Volume and Mortality After Carotid Artery Stenting Among Medicare Beneficiaries; Circ Cardiovasc Qual Outcomes, 72 (3): 276-86, 2016*
104. *Kumamaru H, Gagne JJ, Glynn RJ,* ***Setoguchi S****, Schneeweiss S; Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications; J Clin Epidemiol., 76: 200-8, 2016.*
105. *Kumamaru H, Schneeweiss S, Glynn RJ,* ***Setoguchi S****, Gagne JJ; Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data; Emerg Themes Epidemiol., 13:5, 2016.*
106. *Mi X, Hammill BG, Curtis LH, Lai CC,* ***Setoguchi S****; Use of the Landmark Method to Address Immortal Person-Time Bias in Comparative Effectiveness Research: A Simulation Stud;. Statistics in Medicine, 35(26): 4824-4836, 2016.*
107. *Jalbert JJ, Gerhard-Herman MD, Nguyen LL, Jaff MR, Kumamaru H, Williams LA, Chen CY, Liu J, Seeger JD, Rothman AT, Schneider P, Brott TG, Tsai TT, Aronow HD, Johnston JA,* ***Setoguchi S****; Comparative Effectiveness of Carotid Artery Stenting versus Carotid Endarterectomy Among Medicare Beneficiaries; Circ Cardiovasc Qual Outcomes, 9(3): 275-85, 2016*
108. *Lai CC, Kao-Yang Y, Yang YK, Lin SJ, Wong MB,* ***Setoguchi S****; Comparative Persistence of Antiepileptic Drugs in Patients with Epilepsy: A STROBE-compliant Retrospective Cohort Study; Medicine, 95(35): e4481, 2016.*
109. *Jarrow J, Schanberg LE,* ***Setoguchi S,*** *Hasselblad V, Mellins ED, Schneider R, and Kimura Y, and the CARRA Legacy Registry Investigators; The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis & Rheumatology Research Alliance Registry: 2010-2013; The Journal of Rheumatology, 43(9): 1755-1762, 2016.*
110. *Kinjo M, Lai CC, Korhonen MJ, McGill RL,* ***Setoguchi S****; Potential Contribution of Lifestyle and Socioeconomic Factors to Healthy User Bias in Antihypertensives and Lipid-Lowering Drugs; Open Heart, 4: e000417, 2017.*
111. *Ooba N,* ***Setoguchi S****, Sato T, Kubota K; Lipid-Lowering Drugs and Risk of New-Onset Diabetes: A Cohort Study Using Japanese Healthcare Data Linked to Clinical Data for Health Screening; BMJ Open, 7(6): e015935, 2017*
112. *Koram N, Delgado M, Stark JH,* ***Setoguchi S****, de Luise C; Validation studies of claims data in the Asia-Pacific region: A comprehensive review. Pharmacoepidemiol Drug Saf. 2018;1-15.*
113. *Lai EC, Ryan P, Zhang Y, Schuemie M, Hardy NC, Kamijima Y, Kimura S, Kubota K, Man KK, Cho SY, Park RW, Stang P, Su C, Wong IC, Yang YK,* ***Setoguchi S;*** *Applying a Common Data Model to Asian Databases for Multinational Pharmacoepidemiologic Studies: Opportunities and Challenges. Clinical Epidemiology 2018 Jul 27;10:875-885*
114. *Dinan MA, Curtis LH,* ***Setoguchi S****, Cheung WY; Advanced imaging and hospice use in end-of-life cancer care. Support Care Cancer. 2018* *Oct;26(10):3619-3625*
115. *Koram N, Delgado M, Stark JH,* ***Setoguchi S****, de Luise C. Validation studies of claims data in the Asia-Pacific region: A comprehensive review. Pharmacoepidemiol Drug Saf. 2018;1-15.*
116. *Lai EC, Shin J, Kubota K, Man KK, Park BJ, Pratt N, Roughead NE, Wong IC, Yank YK,* ***Setoguchi S****. Comparative Safety of NSAIDs for Gastrointestinal Events in Asia-Pacific Populations: A Multi-Database, International Cohort Study. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1223-1230*
117. *Ando T, Ooba N, Mochizuki M, Koide D, Kimura K, Lee SL,* ***Setoguchi S****, Kubota K. Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: a validation study at a single center. BMC Health Services Research, 2018*
118. *Kubota K, Kamijima Y, Kao Yang YH, Kimura S, Chia-Cheng Lai E, Man KKC, Ryan P, Schuemie M, Stang P, Su CC, Wong ICK, Zhang Y,* ***Setoguchi S****. Penetration of new antidiabetic medications in East Asian countries and the United States: A cross-national comparative study. PLoS One. 2018 Dec 12;13(12):e0208796.*
119. *Li W, Zou T, Li L, Deng Y, Sun V, Zhang Q, Layton JB,* ***Setoguchi S****. Impacts of the North Atlantic Subtropical High on Interannual Variation of Summertime Heat Stress over the Conterminous United States. Climate Dynamic, in press*
120. *O’Brien EC, Rodriguez, AM, Kum HC, Schanberg LE, Fitz-Randolph M, O’Brien SM,* ***Setoguchi S****. Patient Perspectives on the Linkage of Health Data for Research: Insights from an Online Patient Community Questionnaire. International Journal of Medical Informatics, Int J Med Inform. 2019*
121. *Knox CA, Hampp C, Palmsten K Zhu Y,****Setoguchi S****, Brumback B, Segal R Winterstein AG, Validation of mother-infant linkage using Medicaid Case ID variable within the Medicaid Analytic eXtract (MAX) database. Pharmacoepidemiol Drug Saf. 2019 Pharmacoepidemiol Drug Saf. 2019 Sep;28(9):1222-1230*
122. *Myasoedova E, Davis JM, Matterson EL, Achenbach SJ,* ***Setoguchi S****, Dunlay SM, Roger VL, Gabriel SE, Crowson CS, Increased hospitalization rates following heart failure diagnosis in rheumatoid arthritis as compared to the general population. Seminars in Arthritis and Rheumatism. 2019 2019;S0049-0172(19)30212-4.*
123. *Karr AF, Taylor MT, West LW,* ***Setoguchi S****, Kou TD, Gerhard T, Horton DB. Comparing record linkage software programs and algorithms using real-world data/ PLOS ONE 2019*
124. *Pratt NL, Mack CD, Meyer AM, Davis KJ, Hammill BG, Hampp C,* ***Setoguchi S****, Raman SR,Chun DS, Sturmer T, Lung JL. Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. Pharmacoepidemiol Drug Saf. 2020;29(1):9–17*
125. *Ohnuma T, Raghunathan K, Moore S,* ***Setoguchi S****, Ellis AR, Fuller M, Whittle J, Pyati S, Bryan WE, Pepin, MJ, Bartz RR, Haines KL, Krishnamoorthy V. Dose-Dependent Association of Gabapentinoids with Pulmonary Complications After Total Hip and Knee Arthroplasties. J Bone Joint Surg Am. 2020;102(3):221–229.*
126. *Korhonen MJ, Pentti J, Hartikainen J, Ilomaki J,* ***Setougchi S****, Liew D, Kivimaki M, Vehtera J. Lifestyle Changes in Relation to Initiation of Antihypertensive and Lipid-Lowering Medication: A Cohort Study. J Am Heart Assoc. 2020;9(4)*
127. *Nunez EH, Parchar S, Iwata I,* ***Setoguchi S****, Chen H, Daneault JF; Comparing Different Methods of Gait Speed Estimation using Wearable Sensors in Individuals with Varying Levels of Mobility Impairments; 42nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society; 2020.*
128. *Ilomäki J, Bell JS, Chan AYL, Tolppanen AM, Luo H, Wei L, Lai EC, Shin JY, De Paoli G, Pajouheshnia R, Ho FK, Reynolds L, Lau KK, Crystal S, Lau WCY, Man KKC, Brauer R, Chan EW, Shen CY, Kim JH, Lum TYS, Hartikainen S, Koponen M, Rooke E, Bazelier M, Klungel O,* ***Setoguchi S****, Pell JP, Cook S, Wong ICK. Application of healthcare big data in CNS drug research: The Neurological and mental health Global Epidemiology Network (NeuroGEN), CNS Drugs, in press 2020*
129. *Su CC, Lai EC, Kao Yang Y, Man KC, Kubota K, Stang P, Shuemie M, Ryan P, Hardy C, Zhang Y, Kimura S, Kamijima Y, Wong ICK,* ***Setoguchi S****. Incidence, Prevalence and Prescription Patterns of Antipsychotic Medications Use in Asia and US: A Cross-Nation Comparison with Common Data Model. Journal of Psychiatric Research, J Psychiatr Res. 2020 Aug 27;131:77-84*
130. *Gerhard T, Troup TS, Correll CU,* ***Setoguchi S****, Strom BL, Huang C, Tan Z, Crystal S, Olfson M. Mortality risk of antipsychotic augmentation for adult depression. PLoS ONE 15(9): e0239206*
131. *Layton JB, Li W, Yuan J, Gilman JP, Horton DB,* ***Setoguchi S****. Heatwaves, medications, and heat-related hospitalizations in older Medicare beneficiaries with chronic conditions. PLos ONE in press 2020*

B. Books, Monographs and Chapters

1. ***Setoguchi S****, Fukui T ; Chapter 3. How to teach residents; Communicating with residents; In: Guidebook for clinical teachers; pp49-155; Intermedica, Tokyo; 2002*
2. ***Setoguchi S****, Iwata I; Chapter 3. How to teach residents; Principles of Clinical Education; In: Guidebook for clinical teachers; pp 100-111; Intermedica, Tokyo; 2002*
3. ***Setoguchi S.****; Chapter 5.6. Database Research and Record Linkage; In: Basics of Pharamcoepidemiology; 2009, 2015*
4. ***Setoguchi S****, Douglas IK.; Chapter 26, Comparative Effectiveness Research; In: Pharmacoepidemiology; 2019 6th edition*

C. Patents Held

*N/A*

D. Other Articles (Reviews, Editorials, Letters etc.) In Journals; Chapters; Books; other Professional Communications

1. ***Setoguchi S****, Takeshita A: [Evidence and controversy on clinical use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the treatment of chronic heart failure]. Cardiac Practice 1999; 10(4): 409-413*
2. ***Setoguchi S****, Mohri M; Heart failure and Rennin Angiotensin System; In: Angiotensin II Receptor Blocker; pp 68-77; Sentan-Igakusha, Tokyo; 1999*
3. ***Setoguchi S,*** *Mohri M, Gomi K. [Physical therapy for patients with coronary artery diseases]. Japanese Journal of physical therapy 2001; 35(6): 417-421*
4. *Tanimoto K, Koyama H, Shinbo T, Odagaki T, Kim Y,* ***Setoguchi S****, Taji T, Yang T, Noguchi Z, Matsui K, Sakai T, Okada K, Fukui T. [EBM Round; Antibiotic treatment for acute bronchitis.] EBM Journal 2001; 2(5): 664-669*
5. ***Setoguchi S****, Avorn J, Schneeweiss S; A letter to the editor regarding the Gruber article of May 26, 2005; N Eng J Med, 9:952-3, 2005*
6. ***Setoguchi S. Statin and Cancer in the Elderly. Cardiology Review, September 2007, pp11-13.***
7. *Kinjo M, Kinjo K, Iwata I,* ***Setoguchi S****; A letter to the editor regarding the Rasmussen article of Jan 10, 2007; JAMA, 297(17):1877-8, 2007*
8. ***Setoguchi S. Gender Differences in the Outcome of Myocardial Infarction among the Elderly. Cardiology Review, 2009.***
9. ***Setoguchi S****, Stevenson LW; Hospitalizations in Patients with Heart Failure: Who and Why; J Am Coll Cardiol., 54(18):1703-5, 2009*
10. *Rassen JA, Glynn RJ, Rothman KJ,* ***Setoguchi S****, Schneeweiss S; Response to commentary by Marcus and Gibbons; Pharmacoepidemiol Drug Saf., 2012*
11. *Hlatky MA, Winkelmayer WC, Setoguchi S. Epidemiologic and statistical methods for comparative effectiveness research. Heart Fail Clin. 2013 Jan;9(1):29-36.*
12. *Lai CC, Stang P, Kao Yang YH, Kubota K, Wong ICK, Setoguchi S. International Multi-database Pharmacoepidemiology: Potentials and Pitfalls. Curr Epidemiol Rep (2015) 2: 229. doi:10.1007/s40471-015-0059-z*

E. Abstracts

1. Peer Reviewed Abstracts (a partial list)

*N/A*

1. Non Peer Reviewed Abstracts

*N/A*

F. Reports

 *N/A*

*1. Setoguchi S, Stevenson LW, Nohria A, Schneeweiss S; Limited Contribution of Sudden Death Prevention to Survival after Repeated Heart Failure Hospitalizations; Presented at Heart Failure Society of America Scientific Meeting, Seattle, WA, September 2006*

*2. Setoguchi S, Levin R, Winkelmayer WC; Increased Use of Cardiovascular Drugs Explains Recent Trends in Prognosis after Myocardial Infarction; Presented at American College of Cardiology, 56th Annual Scientific Session, New Orleans, Louisiana, March 2007*

*3. Setoguchi S, Glynn RJ, Flavell CN, Levin R, Stevenson LW; Unchanging Pattern of Low Opiate Use During End-of-Life Care: 8 Years of Medicare Prescription Data; Presented at Heart Failure Society of America Scientific Meeting in Toronto, ON, Canada, September 2008*

*4. Setoguchi S, Higgins JM, Levin R, Mootha V, Avorn, J; Propranolol is Associated with Increased Risk of Hospitalized Myopathy in the Elderly: Validation of a Hypothesis Generated by Chemical Genomics; Presented at American College of Cardiology, 58th Annual Scientific Session, Orlando, Florida, March 2009*

*5. Setoguchi S, Choudhry N, Levin R, Shrank WH, Winkelmayer WC; Trends in Persistence to Evidence-Based Medications after Heart Failure Hospitalization in the Elderly; Presented at American Heart Association, Quality of Care Outcome Research in Cardiovascular Disease and Stroke Conference, Washington D.C., April 2009*

*6. Setoguchi S, Patrick AR, Dormuth C, Glynn RJ, Canning C, Schneeweiss S; Differential Effects of Drug Cost Sharing Policies on Adherence to Angiotensin Blockers in Patients With and Without Heart Failure; Presented at American Heart Association, Quality of Care Outcome Research in Cardiovascular Disease and Stroke Conference, Washington D.C., April 2009*

*7. Setoguchi S, Winkelmayer WC, Levin R, Glynn RJ; Trend in All-Cause and Cardiac Deaths and Use of Cardiovascular Medications after Heart Failure Hospitalization in Seniors; Presented at American Heart Association, Quality of Care Outcome Research in Cardiovascular Disease and Stroke Conference, Washington D.C., April 2009*

*8. Chen CJ, J.J. Williams, L. Rothman, A. Stevenson, L.W. Stewart, G.C. Seeger, J.D. Setoguchi, S; Performance and Validity of Record Linkage without Unique Personal Identifier. Presented at International Congress of Pharmacoepidemiology. Barcelona, Spain: Pharmacoepidemiology and Drug Safety, 2012.*

*9. Setoguchi S, J. Jalbert, J. Chen, CY; Probabilistic vs Deterministic Linkage of Large Device Registries to Medicare Data; Presented at International Congress of Pharmacoepidemiology Barcelona, Spain: Pharmacoepidemiology and Drug Safety, 2012.*

**PRESENTATIONS:**

A. Scientific

*“Evaluating Uses of Data Mining Techniques in Propensity Score Estimation: A Simulation Study,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Bordeaux, France, 2004*

*“Use of Tumor necrosis factor alpha antagonist and Cancer in Patients with Rheumatoid Arthritis,” lecture invitation based on submitted abstract; American College of Rheumatology Annual Meeting, San Francisco, CA, 2005*

*“Limited Contribution of Sudden Death Prevention to Survival after Repeated Heart Failure Hospitalizations,” lecture invitation based on submitted abstract; American Heart Association Annual Scientific Sessions, Chicago, IL, 2006*

*“Repeated Hospitalizations Predict Mortality in the Community Population with Heart Failure,” lecture invitation based on submitted abstract, American Heart Association Annual Scientific Sessions, Chicago, IL, 2006*

*“Cardiovascular Drug Use after Myocardial Infarction in the Elderly,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Lisboa Portugal, 2006*

 *“Tumor Necrosis Factor -alpha Antagonist and Heart Failure in Elderly Patients with Rheumatoid Arthritis,” lecture invitation based on submitted abstract; American College of Rheumatology Annual Meeting, Boston, MA, 2007*

*“Cardiovascular and Infection-related Morbidity and Mortality in Conventional vs. Atypical Antipsychotic Medications in the Elderly,” lecture invitation based on submitted abstract; ASCPT Annual Meeting, Orlando, FL, 2007*

*“Tumor necrosis factor alpha antagonist and heart failure in elderly patients with rheumatoid arthritis,” lecture invitation based on submitted abstract; American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, 2007*

*“Use of Hospice and Acute Care in Heart Failure vs. Cancer at End-of-Life,” lecture invitation based on submitted abstract; American Heart Association Annual Scientific Sessions, New Orleans, LA, 2007*

*“Increased Use of Cardiovascular Drugs Explains Recent Trends in Prognosis after Myocardial Infarction,” invited presentation to Media Conference; American College of Cardiology, New Orleans, LA, 2007*

 *“Cardiovascular and Infection-related Morbidity and Mortality in Conventional vs. Atypical Antipsychotic Medications in the Elderly,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Quebec, Canada, 2007*

*“Tumor necrosis factor alpha antagonist and heart failure in elderly patients with rheumatoid arthritis,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Quebec, Canada, 2007*

*“Increased Use of Cardiovascular Drugs Explains Recent Trends in Prognosis after Myocardial Infarction,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Quebec, Canada, 2007*

*“Unchanging Pattern of Low Opiate Use During End-of-Life Care: 8 Years of Medicare Prescription Data,” Poster presentation, Heart Failure Society of America Scientific Meeting in Toronto, ON, Canada, 2008*

*“Differential Effects of Drug Cost Sharing Policies on Adherence to Angiotensin Blockers in Patients With and Without Heart Failure.” Poster presentation, American Heart Association, Quality of Care Outcome Research in Cardiovascular Disease and Stroke Conference, Washington D.C., 2009.*

*“Trend in All-Cause and Cardiac Deaths and Use of Cardiovascular Medications after Heart Failure Hospitalization in Seniors.” Poster presentation, American Heart Association, Quality of Care Outcome Research in Cardiovascular Disease and Stroke Conference, Washington D.C., 2009.*

 *“Hospice Enrollment and Course in Patients with Heart Failure versus Cancer,” lecture invitation based on submitted abstract; American Heart Association Annual Scientific Sessions, Orlando, FL, 2009*

*“Propranolol and the Risk of Hospitalization for Myopathy in the Elderly: Translating Chemical Genomics Findings into Hypotheses at the Population level,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI, 2009*

*“Use of Medicare Data to Assess Comparative Effectiveness of ACEI vs. ARBs for Hypertension in Patients with Cardiovascular Comorbidities: A Cautionary Tale,” Interim Presentation for DEcIDE Task Order #5; Agency for Healthcare Research and Quality, Bethesda, MD, 2009*

*“Symposium: Methodological Controversies from Comparative Effectiveness (CE) Studies Using Claims vs. Electronic Health Record (EHR) Data,” Invited Lecturer; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK, 2010*

*“Challenges in Assessing Comparative Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension Using Medicare Data,” Invited Lecturer; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK, 2010*

*“Validity of Claims-based Definitions of Left Ventricular Systolic Dysfunction in Medicare Patients,” Invited Lecturer; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK, 2010*

*“Oral abstract session for cardiovascular pharmacoepidemiology,”Invited Moderator; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK, 2010*

*“Association Study,” invited speaker for Asian Pharmacoepidemiology Network Symposium; 5th Asian Pharmacoepidemiology Conference, Tokyo, Japan, 2010*

*“Validity of Exposure and Outcomes,” invited session chair; Agency for Healthcare Research and Quality, 3rd Symposium for Comparative Effectiveness Research Methods: Methods for Developing and Analyzing Clinically Rich Data for Patient Centered Outcome Research, Rockville, MD, 2011*

*“Use and Outcomes of Partial Knee Replacement (PKR) vs. Total Knee Replacement (TKR) Among Medicare Beneficiaries, 2000-2009,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, 2011*

*“Cardiovascular Safety of Dementia Drugs Among Medicare Beneficiaries,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, 2011*

*“AsPEN Association Study II: Introduction and Overview,” invited speaker and panelist in AsPEN (Asian Pharmacoepidemiology Network) Symposium; 6th Asian Pharmacoepidemiology Conference, Beijing, China, 2011*

*“Practice of Device Safety and Effectiveness Research in Era of UDIS: Opportunities and Challenges,” Invited lecturer in Unique Device Identification Symposium; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 2012*

*“Personal Health Record and Patient Reported Outcome for CER: A New Horizon?,” Invited lecturer in CER symposium; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 2012*

*“Cross-National or Multi-Database Research Networks: A New Initiative in Asia-Pacific Region and Ongoing Initiatives in Europe and US;” Symposium organizer International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 2012*

*‘Probabilistic vs Deterministic Linkage of Large Device Registries to Medicare Data.”, lecture invitation based on submitted abstract; International Congress of Pharmacoepidemiology Barcelona, Spain: Pharmacoepidemiology and Drug Safety; 2012.*

 *“Utilization of Cardiovascular Drugs,” Invited co-chair for oral abstract session; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 2012*

 *“Baseline Burden of Heart Failure Limits Duration of Benefit of ICD for Medicare Recipients”, lecture invitation based on submitted abstract; American College of Cardiology Annual Scientific Sessions, Chicago, IL, 2012*

*“Comparative Cardiovascular Safety of Dementia Medications: A Cross-National Study,: lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 2012*

*“ICD Prevent Hip Fracture in Medicare Beneficiaries,” lecture invitation based on submitted abstract; American Heart Association, Dallas, TX, 2013*

*“Comparing Validity of Methods to Select Appropriate Cutoff Weight for Probabilistic Linkage without Unique Identifiers,” lecture invitation based on submitted abstract; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Taiwan, 2014*

*Opening Remarks, ICPE Chair – Scientific Program Committee; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Taipei, Taiwan, 2014*

*“Beyond Descriptive Studies: Role of Pharmacoepidemiology in Understanding Gender Differences,” Invited Lecturer; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Taipei, Taiwan, 2014*

*“Assessing Real World Effectiveness of Primary ICDs in Medicare Patients,” lecture invitation based on submitted abstract; American Heart Association Annual Scientific Session, Orlando, FL, 2015*

*“Deterministic vs. Probabilistic Record Linkage using Multiple Indirect Personal Identifiers: Linking Large Registries to Claims Data,” lecture invitation based on submitted abstract; American Sociological Association Annual Meeting, Chicago, IL, 2015*

*“It Takes a Village: Raising a Global Community of Pharmacoepidemiologists Through High-Quality Education,” Invited Lecturer; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada, 2017*

*“Data Linkage and Patient Perspectives: Insights from a survey in the United States,” lecture invitation based on submitted abstract; 10th Asian Pharmacoepidemiology Conference, Brisbane, Australia, October 2017*

*“Validation of Large Administrative Data: Methodological and Practical Challenges,” Panelist; 10th Asian Pharmacoepidemiology Conference, Brisbane, Australia, 2017*

*“It Takes a Village Part II: Workshop on Core Competencies for New Generations in the Global and Rapidly Changing Community of Pharmacoepidemiology,” Oral Presenter and Co-moderator, 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic, August 2018,*

*“International Comparison of Approaches to Common Data Models for Comparative Effectiveness Research,” Oral Presenter, The International Population Data Linkage Conference, Banff, Canada, September 2018*

*“VALIDATE-J: A Validation Study of Rheumatoid Arthritis in Japanese Claims Data,” lecture invitation based on submitted abstract; ISPE’s 11th Asian Conference on Pharmacoepidemiology, Xi’an, China, October 2018*

*“Heterogeneity and Validity in National and International Multi-Databases Pharmacoepidemiologic Students (MPES): Lessons Learned in North America, Europe, and Asia,” Oral Presenter, ISPE’s 11th Asian Conference on Pharmacoepidemiology, Xi’an, China, October 2018,*

B. Professional

*“Health Services/Outcome Research in Cardiology,” Invited lecturer; Research Seminar, Department of Cardiology, Kyushu University, School of Medicine, Fukuoka, Japan, 2006*

 *“Safety of TNF-Alpha Antagonists:  Focus on Cancer, invited presentation; Arthritis Research Conference (Arthritis Foundation), Stone Mountain, Georgia, 2007*

*“Educational Sessions’; Asian Meeting, Joint Conference by International Society of Pharmacoepidemiology and Japanese Society of Pharmacoepidemiology, Tokyo, Japan, 2007*

*“Data Sources for Pharmacoepidemiology Research,” Invited Lecturer; Seminar in Pharmacoepidemiology sponsored by Unions of Japanese Scientists and Engineers and University of Tokyo, Chiba, Japan, 2008*

*“End of Life Care in Heart Failure”, Guest presenter, Partners Palliative Care Committee, Boston, MA, 2008.*

*“Methods to Improve End of Life Care in Heart Failure,” Guest speaker at Research Conference in Center for Bioethics, Boston, MA 2009.*

*“Outcomes and End-of-life Care in Community Patients after Heart Failure Hospitalizations,” Invited Lecturer; Center for Clinical and Genetic Economics, Duke Clinical Research Center, Durham, NC, 2009*

*“Program Guideline for Comparative Effectiveness Research: Study Protocols: Comparison(s),” Invited Lecturer; Agency for Healthcare Research and Quality 2009 Annual Conference, Bethesda, MD, 2009*

 *“Comparative Effectiveness of Angiotensin Blockers for Hypertension in Elderly Patients with Cardiovascular Comorbidities,” invited presentation; Agency for Healthcare Research and Quality, Bethesda, MD, 2009*

*“Data Sources for Pharmacoepidemiologic Studies,” Invited Lecturer; Seminar in Pharmacoepidemiology sponsored by Unions of Japanese Scientists and Engineers and University of Tokyo, Kanagawa, Japan, 2009*

*“Basic Pharmacoepidemiology,” Invited Lecturer; Office of Safety, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan, 2009*

*“Basic Pharmacoepidemiology,” Invited Lecturer; The Japanese Association of Pharmaceutical Medicine, Tokyo, Japan, 2009*

*“Propensity Score Analysis in Pharmacoepidemiology,” Invited Lecturer; National Cheng Kung University, Tainan, Taiwan, 2009*

*“How to publish your manuscripts,” Invited Lecturer; National Cheng Kung University, Tainan, Taiwan, 2009*

*“Opportunities and Challenges in Observational Comparative Effectiveness Research,” Invited Lecturer; The ASCPT Annual Meeting March 17-20 in Atlanta, Georgia, 2010*

*“Making Large Data Sets Work for You: Advantages and Challenges of Working with Large Data Sets,” Invited Lecturer; American Heart Association and Program Committee for the Quality of Care and Outcomes Research in Cardiovascular Care and Stroke 2010 Scientific Sessions, May, Washington DC, 2010*

*“CER guide outline presentation,” Presenter; Agency for Healthcare Research and Quality, Annual Meeting, Bethesda, MD, 2010*

*“CMS coverage symposium,” invited presenter and panelist; Agency for Healthcare Research and Quality, Annual Meeting, Bethesda, MD, 2010*

*“Evaluating Drug Effectiveness and Safety Using Observational Data:
A Pharmacoepidemiologist’s Perspective,” Invited lecturer; American Heart Association 2010 Annual Scientific Session, November, Chicago, IL, 2010*

*"Large databases and training in Pharmacoepidemiology: US and Japan," Invited lecturer; Scientific meeting in pharmacoepidemiology, University of Tokyo, Tokyo, Japan, 2010*

*“Cohort Study” in Introductory Pharmacoepidemiology Course, Invited Lecturer; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Brighton, UK, 2010*

*“Current and Future Status of Database Research in the US: Examples from 1) database study to assess the effect of glucose control in patients with type II diabetes 2) Pharmacoepidemiologic studies to evaluate the risk of cancer in drug users,” Invited Lecturer; The Diabetes Mellitus Summit, Tokyo, Japan, 2010*

*“Introduction to Pharamcoepidemiology: How to Conduct Safety Studies,” Invited Lecturer ; For the officers of the Japanese Pharmaceuticals and Medical Devices Agency, Tokyo, Japan, 2010*

*“Large-Scale RA Cohort Studies and Safety of Biologics,” invited moderator; The International Symposium for Safety of Biologics in Patients with Rheumatoid Arthritis, Tokyo, Japan, 2010*

*“Biologics and Risk of Cancer in Patients With Rheumatoid Arthritis: Recent Safety Studies in US Databases,” Invited Lecturer; The International Symposium for Safety of Biologics in Patients with Rheumatoid Arthritis, Tokyo, Japan, 2010*

*“Cohort Study,” Invited Lecturer for Educational Session for Basic Pharmacoepidemiology; 5th Asian Pharmacoepidemiology Conference, Tokyo, Japan, 2010*

*“Bias and Confounding,” Invited Lecturer for Educational Session for Basic Pharmacoepidemiology; 5th Asian Pharmacoepidemiology Conference, Tokyo, Japan, 2010*

 *“Resources for Pharmacoepidemiology Research in the US,” Invited Lecturer; Seminar in Pharmacoepidemiology sponsored by Unions of Japanese Scientists and Engineers and University of Tokyo, Tokyo, Japan, 2010*

*“Methodology Session,” invited panelist; FDA Medical Device Epidemiology Network Public Workshop, Bethesda, MD, 2011*

 *“Medical Device Identification in National and Hospital-Based Registries: Current Status and Utility for Postmarketing Surveillance,” invited speaker and panelist in Registry Session; FDA Unique Device Identification Public Workshop, Bethesda, MD, 2011*

*“Chapter 6: Comparisons for Comparative Effectiveness Research Guide,” invited presenter; Agency for Healthcare Research and Quality, Annual Conference, Bethesda, MD, 2011*

*“Real World Effectiveness of Implantable Cardioverter Defibrillators in Medicare Patients,” invited presenter; Agency for Healthcare Research and Quality, Annual Conference, Bethesda, MD, 2011*

*“DEcIDE Method Webinar ‘Linking Claims Data & Registry Information in CER,” Invited Lecturer; Monthly DEcIDE Method Webinar, Boston, MA, 2011*

*“Current and Future Status of Clinical and Pharmacoepidemiologic Research in the US,” Invited Lecturer; Seminar Series for Clinicians, Kyushu Koseinenkin Hospital, Kitakyushu, Japan, 2011*

*“Bias and Confounding,” Invited Lecturer for Educational Session for Basic Pharmacoepidemiology; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, 2011*

*“Introduction,” “Healthy Users, Sick Stoppers, and Confounding by Indication in Device CER: A Case of Implantable Cardioverter Defibrillators,” organized and invited lecture for CER SIG Supported Symposium: Lessons from an Ongoing Comparative Effectiveness Research (CER) Project: Database Linkage and Methodological Issues in Medical Devices vs. Medications; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, 2011*

 *“Introduction to Pharmacoepidemiology,” “Data Sources for Pharmacoepidemiology,” “Cohort Study Using Large Databases,” “Bias and Confounding in Pharmacoepidemiology Using Large Databases,” and “Protocol Writing for Pharmacoepidemiology Using Large Databases,” director and Invited Lecturer; Two-Day Public Workshop in Pharmacoepidemiology Research Using Large Databases, Tokyo, Japan, 2011*

*“Resources for Pharmacoepidemiology Research in the US,” Invited Lecturer; Seminar in Pharmacoepidemiology sponsored by Unions of Japanese Scientists and Engineers and University of Tokyo, Kisarazu, Chiba, Japan, 2011*

*“Secondary Use of Healthcare Data in the US: Current Status and Future Directions in Pharmacoepidemiology,” invited speaker and panelist; Drug Information Association Japan Meeting, Tokyo, Japan, 2011*

*“Challenges and Opportunities in Drug Safety Research Using Emerging Databases in Asia,”, Plenary Speech; 6th Asian Pharmacoepidemiology Conference, Beijing, China, 2011*

*“Opportunities and Challenges in Observational Comparative Effectiveness Research,” Invited, Chung Kuang University, Taiwan; Invited lecturer at Chung Kuang University, Tainan, Taiwan, 2011*

*“Using Pharmacoepi Tools to Evaluate the Impact of Interventions: Overview of Available Study Designs to Analyze the Impact of Interventions,” Invited Lecturer; EuroDURG/ISPE meeting - “Better public health through pharmaco-epidemiology and quality use of medicine,” Antwerp, Belgium, 2011*

*“State-of-the-art in Research on the Impact of Interventions: From Pharmacoepidemiologist’s Perspective,” Plenary Lecturer; EuroDURG/ISPE meeting - “Better public health through pharmaco-epidemiology and quality use of medicine”, Antwerp, Belgium, 2011*

*“Record Linkage for Comparative Effectiveness Research: Why and How,” Invited Lecturer; Comparative Effectiveness Research Symposium, University of Alabama Birmingham, Birmingham, AL, 2012*

*“Leveraging Existing Resources for Postmarket Studies for Medical Devices,” invited lecture and panelist; FDA CDRH Public Workshop for Section 522, FDA, Silver Spring, MD, 2012*

*“Methodological Considerations in Comparative Effectiveness Research for Medical Devices,” lecture invitation; Seminars in Pharmacoepidemiology Method, University of North Carolina, School of Public Health, Chapel Hill, NC, 2012*

*“Immortal Person Time Bias in CER for Cardiovascular Devices;” invited lecturer, AHRQ CER Method Symposium, Bethesda, MD, 2012*

*“Can We Adjust Populations to Measure Effectiveness,” Invited Lecturer in Concurrent Symposium for ‘Revised AHA/ACC Performance Measures and Evidence That Supports Changes;’ Annual Meeting for Heart Failure Society for America, Seattle, WA, 2012*

*“Methodological Considerations in Comparative Effectiveness Research for Medical Devices,” Invited Lecturer; CER Seminar, Duke Clinical Research Institute, Durham, NC, 2012*

*“Final Results of Real World Effectiveness of Implantable Cardioverter Defibrillators and Carotid Stenting in Medicare Patients,” Invited lecturer; Agency for Healthcare Research and Quality, Bethesda, MD, 2012*

*“Linking Multiple Databases and Other Methodological Considerations in Postmarket Studies of Implantable Devices,” Invited Lecturer; Training Session at CDRH, FDA, Silver Spring, MD, 2012*

*“Linking Multiple Databases and Other Methodological Considerations in Postmarket Studies of Implantable Devices,” Invited Lecturer; Device Epidemiology Course, Harvard School of Public Health, Boston, MA, 2012*

*“Pharmacoepidemiology - Analyses of Data To Understand Use, Safety and Effectiveness of Medications,” Invited Lecturer; Pediatric Research Conference, Durham, NC, 2012*

*“Bias and Confounding,” Introduction to Pharmacoepidemiology, Invited lecturer; Mid-year symposium for International Society of Pharmacoepidemiology, Miami, FL, 2012*

*“Synthesis of Information of Observational Data for Decision Makers,” Invited co-chair; Mid-year symposium for International Society of Pharmacoepidemiology, Miami, FL, 2012*

*“Introduction and Logistics,” Invited lecturer in Medical Device Epidemiology Course; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 2012*

*“Linking Data Sources and Methodological Considerations in Postmarketing Studies for Cardiovascular Medical Devices,” Invited lecturer in Medical Device Epidemiology Course; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, 2012*

*“Resources for Pharmacoepidemiology Research in the US,” Invited Lecturer; Seminar in Pharmacoepidemiology sponsored by Unions of Japanese Scientists and Engineers and University of Tokyo, Kisarazu, Chiba, Japan, 2012*

*“Introduction and Principles of Cohort Design,” Invited Lecturer in ‘Introduction to Pharmacoepidemiology without Databases;’ 7th Asian Pharmacoepidemiology Conference, Bangalore, India, 2012*

*“Case-Control Design,: Co-director and Invited Lecturer in ‘Introduction to Pharmacoepidemiology without Databases;’ 7th Asian Pharmacoepidemiology Conference, Bangalore, India, 2012*

*“Experience from Recent Large Comparative Effectiveness Studies: Linking multiple databases and Methodological Considerations,” Invited Lecturer in CER Symposium; Seventh Asian Pharmacoepidemiology Conference, Bangalore, India, 2012*

*“Comparative Safety of NSAIDs in Asian Population: A Preliminary Report,” invited speaker and panelist in AsPEN (Asian Pharmacoepidemiology Network) Symposium; 7th Asian Pharmacoepidemiology Conference, Bangalore, India, 2012*

*“How To Write An Abstract for A Scientific Conference,” Invited Lecturer; Epidemiology Course, Duke Global Research Institute, Durham, NC, 2013*

*“International Database Network Research: Experience in AsPEN and Others,” Invited Lecturer; Seminars in Pharmacoepidemiology Method, Department of Epidemiology, University of North Carolina School of Public Health, Chapel Hill, NC, 2013*

*“Methods to Assess Medication Adherence,” Invited Lecturer; Annual Conference for American Society of Clinical Oncology, Chicago, IL, 2013*

*“Application of Pharmacoepidemiology Methods to CER and Global Research Network,” Invited Lecturer; Research Conference, Duke Clinical Research Institute, Durham, NC, 2013*

 *“Best Practice in Clinical Research Using Databases,” Invited Lecturer; Symposium on Globalization of Clinical Research and Trial, University of Tokyo, Japan, 2013*

*“Current Status and International Collaboration for Clinical Research at Duke Clinical Research Institute,” Invited lecturer; Special Seminar, Jichi Medical University, Tochigi, Japan, 2013*

*“Validation Studies: Large database research to form evidence in clinical medicine,” Director and Invited Lecturer; Public Workshop in Large Database Research, sponsored by Division of Pharmacoepidemiology, University of Tokyo, Tokyo, Japan, 2013*

*“Leveraging Existing Data Sources for Clinical and Epidemiologic Research; Linking Registries, Electronic Health Records, and Claims Data,” Invited lecturer; International Symposium on Development of Medical Technologies for Treating Intractable Cancers and Cardiovascular Diseases. Tokyo, Japan, 2013*

*“Use and Impacts of Claims Databases in Pharmacoepidemiology and Device Epidemiology in the US,” Invited lecturer; Japan Medical Data Center Seminar, Tokyo, Japan, 2013*

*“How to Deal with Exposure in Pharmacoepidemiology,” Invited lecturer; Public Workshop in Advanced Pharamcoepidemiology, sponsored by Division of Pharmacoepidemiology, University of Tokyo, Tokyo, Japan, 2013*

*“Observational Comparative Effectiveness Research: Examples and Methodological Challenges,” Invited Lecturer; 8th Asian Pharmacoepidemiology Conference, Hong Kong, 2013*

*“Technology Assessment and Database Research,” Invited Lecturer; International Seminar in Clinical Research, Tokyo Japan, 2014*

*“Healthy User Bias in Observational Studies,” Invited Lecturer; Symposium in Pharmacoepidemiology and Pharmacoeconomics, hosted by Medical Society of Finland, Finland, 2014*

*“Basic Database Analysis in Pharmacoepidemiology,” Invited Lecturer; Symposium in Pharmacoepidemiology and Pharmacoeconomics, hosted by Medical Society of Finland, Finland, 2014*

*“Practical Skills in Protocol Writing and Computer Programming relevant to Pharmacoepidemiology,” Invited Lecturer; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Taipei, Taiwan, 2014*

*“Linking Data for CER/PCOR: How to Link and Analyze,” Invited Lecturer; PCOR Symposium, University of Washington St. Louis, St. Louis, MO 2015*

 *“Pharmacoepidemiologic Research: Experiences from USA for Asian Countries,” Plenary Speech,; 9th Asian Conference on Pharmacoepidemiology, Bangkok, Thailand, 2015*

 *“Introduction: New Privacy Law and Ethical Considerations for Clinical Research in Japan,” Invited Lecturer; Pfizer Advisory Board for Research Ethics in Japan, Tokyo, Japan, 2016*

*“Validation Study of Claims-based Definitions for Rheumatoid Arthritis, Infectious Disease, and Cancer,” Invited Lecturer; Pfizer Advisory Board for Validation Studies, Tokyo, Japan, 2016*

*“Practical skills in protocol writing and computer programming relevant to Pharmacoepidemiology,” Invited Lecturer; International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada, 2017,*

*“Non-statistical methods to combat bias in CER: design-based methods and data linkage,” Invited Lecturer; 10th Asian Pharmacoepidemiology Conference, Brisbane, Australia, 2017*

*“Record Linkage: Methods, Patient Perception, and Applications in Database Research,” Invited Speaker, Rutgers Institute for Health Brown Bag Seminar, New Brunswick, NJ, February 2018,*

*“From Bedside to Population Science: Opportunities for Clinical Research Using Big Data,” Oral Presenter,* ***Keynote Address****, Rutgers Robert Wood Johnson Medical School Resident Research Day, New Brunswick, NJ, May 2018,*

 *“Data Sources for Pharmacoepidemiologic Studies,” Invited Lecturer; Seminar in Pharmacoepidemiology sponsored by Unions of Japanese Scientists and Engineers and University of Tokyo, Kanagawa, Japan, October 2018*

 *“Toward Age-Friendly Health System Research in Vulnerable Aging Population,” Invited Speaker, Rutgers Robert Wood Johnson Barnabas Health Academic Health Symposium, Piscataway, NJ, October 2018,*

 *“Clinical Research and Big Data: Creating Opportunities for Residents,” Invited Lecturer, Rutgers Robert Wood Johnson Medical School Internal Medicine Intern Research Retreat, New Brunswick, NJ, November 2018*

*“Opportunities for Clinical Research Using Big Data,” Invited Speaker, Ground Round, Princeton Hospital, Penn Medicine, Princeton, NJ, February 2019*

*“Climate-drug interactions, part 2:Heat-related outcomes and medication use in older adults with chronic diseases and more’ Speaker, Summer Institute for Causal Inference 2019, New Brunswick, NJ, July 2019*

*“Big Data and Clinical Research,” Invited Speaker, Ground Round, Princeton Health,*

*“Health Outcomes in Asian Older Adults under Extreme Heat and Medication Use”. RCMAR Retreat, New Brunswick, NJ, September 2020*

 *“Real World Data and Data Environment In Japan” Invited Lecturer, Merck Inc. Epidemiology Conference, Virtual, August, 2020*

*“Understanding Interactions Between Heatwaves, Air Pollution, and Medications: Methodological Challenges”, Invited Plenary Speaker, Hot Topic Session, International Conference on Pharmacoepidemiology and Therapeutic Risk Management, All Access (Virtual), 2020*

*“Extreme Heat, Air Pollution, and Medication- Understanding Impact of Extreme Heat and Air Pollution and Their Interaction with Medication Use in Older Adults “, Invited Speaker, Departmental Seminar, Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Virtual, September 2020*

*“Real World Data and Data Environment In Japan” Invited Lecturer, Merck Inc. Edpiemiology Conference, Virtual, August, 2020*

 *“Introduction to Research Program”, Invited Lecturer, Pharmaco- and Device- Epidemiology Research Unit, Oxford University, November 2020*